ACB

ISS has recommended that Aurora's shareholders vote FOR all director nominees and meeting resolutions Shareholders are encouraged to vote early in favour of all resolutions – every vote matters, no matter how many shares you own Shareholders who have questions or need assistance with voting their shares should contact Aurora's strategic advisor and proxy solicitation agent, Kingsdale Advisors, by telephone at 1-800-749-9052 or by email at   contactus@kingsdaleadvisors.com  or visit  www.MyAuroraVote.com EDMONTON, AB, July 27, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora" or the "Company"), the Canadian-based leading global medical cannabis company, is pleased to announce that  Institutional Shareholder Services Inc. (ISS), the leading independent proxy advisory firm whose voting recommendations are widely relied upon by major institutional investors, has recommended that Aurora's shareholders vote FOR all resolutions set forth in the Company's management information circular (the "Circular") in advance of its upcoming Annual General Meeting of Shareholders. The Circular is available on the Company's website and under Aurora's profile on SEDAR+.

The achievement strengthens Safari's ability to serve international medical cannabis markets under the strictest regulations EDMONTON, AB, July 23, 2026 /PRNewswire/ -- Safari Flower Company ("Safari"), a wholly owned subsidiary of Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), is proud to announce the receipt of European Union Good Manufacturing Practice ("EU-GMP") certification for its Ontario facility, solidifying its ability to serve international medical cannabis markets. The certification is granted for a three-year term and validates Safari Flower Company's unwavering commitment to meeting the highest international standards for quality, compliance and operational excellence.

NASDAQ | TSX: ACB EDMONTON, AB, July 22, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that will host an investor conference call on Wednesday, August 5, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m.

Aurora Cannabis' shares plunge 28% in three months as a cautious fiscal 2027 outlook overshadows record medical cannabis growth and global expansion.

NASDAQ | TSX: ACB The Company makes history as the first and only cannabis company to ever receive this recognition EDMONTON, AB, July 9, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora" or the "Company"), the Canadian-based leading global medical cannabis company, has been awarded on TIME Canada's Best Companies 2026 list. This win reflects the Company's differentiated performance and commitment to industry excellence.

Shareholders are encouraged to keep an eye out for their meeting materials and vote  early – every vote matters, no matter how many shares you own. Shareholders who have questions or need assistance with voting their shares voting should contact Aurora's strategic advisor and proxy solicitation agent, Kingsdale Advisors by telephone at 1-800-749-9052 or by email at  contactus@kingsdaleadvisors.com or visit www.MyAuroraVote.com EDMONTON, AB, July 8, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX: ACB) (NASDAQ: ACB), a leading Canada-based global medical cannabis company, is pleased to announce that the management information circular (the "Circular") for the upcoming annual general meeting of shareholders is now available on the Company's website at www.auroramj.com/investors/corporate-governance as well as under its profile on SEDAR+ (www.sedarplus.ca).

ACB frames fiscal 2027 as a reset year as Canadian reimbursement pressure weighs on margins, even as global medical cannabis growth continues.

Aurora Cannabis reported Q4/FY2026 results largely in line with expectations previously outlined by management. In recent months, the company has made the strategic decision to exit its lower margin consumer cannabis and plant propagation operations and focus on the growing European medical cannabis market. However, FY2027 will be impacted by adverse regulatory changes in the Canadian medical cannabis market. As a result, sales and margins are expected to decline quite meaningfully this year.

Aurora Cannabis NASDAQ: ACB reported a stronger fiscal 2026 performance than it had forecast, driven by growth in global medical cannabis, while warning that fiscal 2027 will be a “reset year” as Canadian medical reimbursement changes weigh on revenue and margins.